J. L. Bainbridge & Co., Inc. Biogen Inc. Transaction History
J. L. Bainbridge & Co., Inc.
- $1.05 Billion
- Q4 2024
A detailed history of J. L. Bainbridge & Co., Inc. transactions in Biogen Inc. stock. As of the latest transaction made, J. L. Bainbridge & Co., Inc. holds 97,983 shares of BIIB stock, worth $13.8 Million. This represents 1.43% of its overall portfolio holdings.
Number of Shares
97,983
Previous 121,142
19.12%
Holding current value
$13.8 Million
Previous $23.5 Million
36.19%
% of portfolio
1.43%
Previous 2.29%
Shares
4 transactions
Others Institutions Holding BIIB
# of Institutions
1,000Shares Held
131MCall Options Held
1.77MPut Options Held
2.34M-
Vanguard Group Inc Valley Forge, PA16.7MShares$2.35 Billion0.05% of portfolio
-
Primecap Management CO Pasadena, CA16MShares$2.25 Billion1.94% of portfolio
-
Black Rock Inc. New York, NY14.5MShares$2.04 Billion0.08% of portfolio
-
State Street Corp Boston, MA7.4MShares$1.04 Billion0.05% of portfolio
-
Wellington Management Group LLP Boston, MA4.93MShares$693 Million0.14% of portfolio
About BIOGEN INC.
- Ticker BIIB
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 144,000,992
- Market Cap $20.2B
- Description
- Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...